EnzyDock-based Multistate and Multiscale Tools for Covalent Drug Design
Project Number5R21GM148895-02
Contact PI/Project LeaderNAM, KWANGHO
Awardee OrganizationUNIVERSITY OF TEXAS ARLINGTON
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
In recent years, FDA has approved a growing number of drugs that are covalently linked to target biological
molecules. To expand the development of covalent inhibitors, technologies more specific to the discovery of
such inhibitors are needed. It is also necessary to address concerns regarding off-site reactivity and toxicity
associated with covalent drugs. The particular focus of this proposal is to develop multiscale in silico covalent
docking approaches by integrating robust quantum mechanical and molecular mechanical (QM/MM) potentials
with the EnzyDock docking platform, thus enabling explicit modeling of multi-step chemical events and their
energetic contributions during the search for docked poses. Current docking approaches lack the ability to
perform covalent bond formation in a manner consistent with an inhibitor’s pre-covalent binding mode, as well
as with the reaction transition state and covalently bonded mode. This wanting ability not only hampers the
fundamental understanding of warhead-target reactivity, but also poses a technical barrier for advancing in silico
docking strategies. Indeed, many existing docking programs offer the capacity to perform covalent docking but
in an ad hoc fashion, as covalent docking was not considered from the design phase of the program development.
With the goal to overcome this technical challenge, two specific aims are: AIM 1 is to develop a multiscale
QM/MM/EnzyDock covalent docking method. In this development, EnzyDock will serve as the primary docking
platform and robust semiempirical QM/MM potentials will be developed, calibrated for each specific warhead-
target reaction type and combined with EnzyDock. In addition, we will develop and implement the generalized
Born (GB) solvation model with the QM/MM potential framework to improve the energetics of QM/MM-docked
poses. AIM 2 will apply the QM/MM/EnzyDock approach developed in AIM 1 to establish effective workflow for
in silico screening of large covalent inhibitor databases. Specifically, two workflows will be explored: The first
workflow is based on docking with a predefined covalent attachment site, which is employed in most covalent
docking programs. The second workflow entails a dynamic approach to covalent docking, in which covalent
attachment sites on the ligand are searched and determined on the fly during docking using cheminformatics
analysis and spatial proximity with target residues in the binding pocket. In this research, the study will be limited
to the warheads that react only with cysteine residues, while additional target residues, reaction types and
warheads will be considered in future research to construct a more comprehensive warhead-target reaction
database. Thus, the two workflows will be tested and benchmarked against known structures and
kinetic/thermodynamic data of drug-Cys covalent systems. We expect that the methods developed in this project
will make the in silico covalent inhibitor discovery more powerful and help understand electrophilic-target
reactivity for use in warhead design and selection.
Public Health Relevance Statement
PROJECT NARRATIVE (RELEVANCE)
In this project, we seek to develop a novel quantum mechanics-based covalent drug docking approach enabling
the determination of warhead-target reaction mechanisms and their kinetic and thermodynamics properties. The
developed approach will overcome the limitation of existing drug docking programs by explicitly modeling
chemical events and facilitate reliable and quick predictions of covalently docked poses and their reactivity
profiles.
No Sub Projects information available for 5R21GM148895-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21GM148895-02
Patents
No Patents information available for 5R21GM148895-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21GM148895-02
Clinical Studies
No Clinical Studies information available for 5R21GM148895-02
News and More
Related News Releases
No news release information available for 5R21GM148895-02
History
No Historical information available for 5R21GM148895-02
Similar Projects
No Similar Projects information available for 5R21GM148895-02